Quest Acquires MyPRS Test

We represented Quest Diagnostics (NYSE: DGX) in its acquisition of intellectual property assets relating to MyPRS test from Signal Genetics (NASDAQ: SGNL). Myeloma Prognostic Risk Signature, or MyPRS, test analyzes the activity of genes to predict whether an individual is at high risk or low risk for early relapse. Knowing the risk of relapse helps to predict patient outcome.

Quest Diagnostics is the world’s leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions.

You Also May Be Interested In:

  • Representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge with Strategic Storage Trust II, Inc., (SST II) in an all-cash merger valued at $340 million expected to close during the first quarter of 2019, subject to customary closing conditions, including the approval of SSGT’s stockholders

    We are representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge...
    Client Type: Private Company
  • Represented Wright Medical Group in its acquisition of Cartiva, Inc.

    We served as lead counsel to Wright Medical Group N.V. (Nasdaq: WMGI) in the acquisition of Cartiva, Inc., a privately-held...
    Client Type: Public Company
  • Represented Ardent Health Services in its agreement with Epic Systems Corp. to unite all Ardent hospitals and clinics under a single information-sharing platform

    We represented Ardent Health Services in its agreement with Epic Systems Corp., the industry's leading provider of electronic health record...
    Client Type: Private Company